A Preclinical Research Scientist plays a crucial role in the transition from basic laboratory findings to clinical application. Their primary focus is evaluating the safety, efficacy, and biological behavior of drug candidates before they are tested in humans. This involves conducting a wide range of in vitro (cell-based) and in vivo (animal-based) experiments to understand how a compound interacts with the body and how the body processes it. Key areas of investigation include toxicity, pharmacokinetics (absorption, distribution, metabolism, and excretion), and pharmacodynamics (how the drug affects biological systems). These studies provide essential data for determining appropriate dosage levels and identifying potential risks.
Working at the interface of discovery and clinical development, Preclinical Research Scientists collaborate with toxicologists, pathologists, regulatory experts, and data scientists to design comprehensive study protocols. They generate detailed reports and interpret complex biological responses to assess whether a compound has a favorable safety margin for human testing. Regulatory guidelines, such as those from the FDA or EMA, shape much of their work to ensure that studies meet the rigorous standards required for Investigational New Drug (IND) applications. Advances in cell modeling, organ-on-chip technology, and predictive analytics are expanding the tools available for this critical stage. Their efforts are foundational in minimizing risk and ensuring that only the most promising and safe drug candidates move forward into clinical trials.
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary